CytomX Therapeutics, Inc. Contract Liability (Deferred Revenue)
CytomX Therapeutics, Inc. (CTMX) had Contract Liability (Deferred Revenue) of $24.07 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Current $24.07M.
- 2026-03-31: Contract with Customer, Liability, Current $17.88M.
- 2025-12-31: Contract with Customer, Liability, Current $26.88M.
- 2025-09-30: Contract with Customer, Liability, Current $22.38M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $24.07M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $17.88M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $26.88M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $22.38M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $22.05M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $33.23M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $67.20M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $96.06M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $123.77M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $123.63M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $132.27M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $124.40M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $120.28M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $126.78M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $121.27M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $87.13M 10-K · filed 2023-03-27 | $61.33M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $60.99M 10-K · filed 2023-03-27 | $65.79M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $54.65M 10-K · filed 2023-03-27 | $70.01M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $40.82M 10-K/A · filed 2023-03-27 | $69.26M 10-K · filed 2022-03-01 |
| 2021-09-30 | $40.84M 10-K/A · filed 2023-03-27 | $73.09M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $39.31M 10-K/A · filed 2023-03-27 | $72.37M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $43.52M 10-K/A · filed 2023-03-27 | $76.64M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $42.06M 10-K/A · filed 2023-03-27 | $74.87M 10-K · filed 2021-02-24 |
| 2020-09-30 | $74.44M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $72.71M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $73.87M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $51.38M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $51.08M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $51.68M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $50.77M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $52.71M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $53.00M 10-Q · filed 2018-11-06 | |
| 2017-12-31 | $40.56M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |